NCT06262477 - A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

September 25, 2024

Study Completion Date

October 4, 2024

Conditions

Healthy Volunteer

Interventions

DRUG

BIIB800

Administered as specified in the treatment arm.

DRUG

Actemra

Administered as specified in the treatment arm.

Trial Locations (4)

Fortrea Clinical Research Unit Inc., Daytona Beach

Fortrea Clinical Research Unit Inc., Madison

Fortrea Clinical Research Unit Inc., Dallas

Fortrea Clinical Research Unit Inc., Leeds